Working backwards: Patient access strategy is now guiding R&D
Drawing from research from across the breadth of Norstella, this white paper lays out the argument for the increasing strategic influence of patient access. The pricing and reimbursement landscape in the US remains volatile as the various stakeholders react to new policies and the increasing complexity of new drug launches. This is creating the conditions […]